Preventive Care System Application Effectiveness Study on the Treatment of Diabetic Patients in Bandung

Launched by PT BIO FARMA · Dec 12, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a special application designed to help manage diabetes in patients with Type 2 Diabetes Mellitus in Bandung. The goal is to see how well this app supports people in controlling their blood sugar levels and improving their overall health. The trial is currently looking for participants aged 18 to 60 who have been diagnosed with Type 2 diabetes and have a specific blood test result indicating their diabetes status. It’s important that participants have a compatible smartphone and internet access since the application will be used on their devices.

If you join this study, you’ll receive regular diabetes treatment and use the app for up to three months. Participants will be monitored to see how well the app helps them manage their condition. However, if you are pregnant, involved in other weight loss programs, using different health tracking apps, or have serious diabetes-related complications, you may not be eligible to participate. This trial aims to find new ways to support individuals with diabetes and improve their care, so if you meet the criteria and are interested, consider participating!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects are in the diabetes type 2 status (based on Perkeni standard) HbA1c is ≥6.5%
• • Aged 18 - 60 years old
• • Have compatible smartphone (minimum android 8 or iOS 13) and internet connection
• • Receiving regular diabetes treatment
• • Giving consent and commitment to participate in the study until finish
• • Located in Bandung Area within the treatment period (up to 3 month after receiving the treatment)
• • Subject is determined to be able to complete daily physical activities.
• Exclusion Criteria:
• • Pregnant (based on test pack)
• • Participation in other weight loss program
• • Use of other tracking application
• • Having any abnormalities that affecting blood erythrocyte age defined by laboratory examination
• • Have other severe diabetic complications that prevent subjects from participating in the prescribed program (Such as stroke, cardiac diseases (CHF stage III-IV), COPD or asthma with acute exacerbation and other respiratory diseases, peripheral artery disease, CKD stage 3-5) and other severe diseases that by the investigator's judgment, could not participate in this study

Trial Officials